1. Articles from Yang C, Tan J, Zhu J, Wang S, Wei G

    1-1 of 1
    1. YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.

      YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.

      Oncotarget. 2017 Mar 15;:

      Authors: Yang C, Tan J, Zhu J, Wang S, Wei G

      Abstract The transcriptional co-activator Yes-associated protein (YAP) is essential for Hippo pathway-driven tumorigenesis in various cancers. However, the expression and function of YAP in neuroblastoma remains elusive. Here, we show that YAP was highly expressed in Neuroblastoma (NB) and expression levels correlated with advanced tumor staging.

      Read Full Article
    1-1 of 1
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (1 articles) Tumorigenesis
    2. (1 articles) Staging
  3. Popular Articles

  4. Picture Gallery

    Fighting cancer with immunotherapy: Signaling molecule causes regression of blood vessels Fighting cancer with immunotherapy: Signaling molecule causes regression of blood vessels Latest data show a global increase of 13% in childhood cancer incidence over two decades Success of sensory cell regeneration raises hope for hearing restoration Study finds more childhood cancer survivors would likely benefit from genetic screening Biomarker may identify neuroblastoma patients most likely to benefit from immunotherapy Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe Lin BioScience Licenses a Novel Anti-Cancer Therapy for Hematological Malignancies and Solid Tumors from Columbia University and Memorial Sloan Kettering Cancer Center As radiation therapy declined so did second cancers in childhood cancer survivors